Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIHUAN PHARM

1.670
0.000
Volume:58.15M
Turnover:96.76M
Market Cap:15.33B
PE:-65.32
High:1.700
Open:1.680
Low:1.640
Close:1.670
52wk High:1.710
52wk Low:0.491
Shares:9.18B
HK Float Shares:9.18B
Volume Ratio:0.42
T/O Rate:0.63%
Dividend:0.01
Dividend Rate:0.65%
EPS(LYR):-0.026
ROE:-6.73%
ROA:-0.93%
PB:3.20
PE(LYR):-65.32
PS:6.68

Loading ...

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Cash Dividend of RMB 0.0099 Per Share

Reuters
·
Aug 29

Sihuan Pharma - Resolved to Declare an Interim Cash Dividend of RMB0.99 Cents per Share

THOMSON REUTERS
·
Aug 29

Sihuan Pharmaceutical Holdings Group H1 Pretax Profit RMB 156.9 Million

THOMSON REUTERS
·
Aug 29

Sihuan Pharmaceutical Holdings Group H1 Operating Profit RMB 264.4 Million

THOMSON REUTERS
·
Aug 29

Sihuan Pharmaceutical Holdings Group H1 Gross Margin 66.1%

THOMSON REUTERS
·
Aug 29

BRIEF-Sihuan Pharmaceutical Says Dirozalkib Tablets Approved By NMPA

Reuters
·
Aug 22

SIHUAN PHARM (00460): Xuanzhu Biotechnology's Self-Developed Innovative Drug Lovalac Tablets Receives NMPA Marketing Approval

Stock News
·
Aug 22

Sihuan Pharmaceutical Holdings Group Ltd - Dirozalkib Tablets Approved by Nmpa

THOMSON REUTERS
·
Aug 22

Hong Kong Stock Alert | SIHUAN PHARM (00460) Surges Over 9% as Subsidiary's Semaglutide Injection Application Accepted by NMPA

Stock News
·
Aug 18

BRIEF-Sihuan Pharmaceutical Says NMPA Accepts NDA Of Semaglutide Injection

Reuters
·
Aug 15

Sihuan Pharmaceutical's Unit Gets China Acceptance for Glycemic Control Drug Application

MT Newswires Live
·
Aug 15

SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical

Stock News
·
Aug 15

Sihuan Pharmaceutical - Nmpa Accepts Nda of Semaglutide Injection by Huisheng Biopharmaceutical

THOMSON REUTERS
·
Aug 15

Sihuan Pharmaceutical Flags H1 Profit; Shares Gain 1%

MT Newswires Live
·
Aug 04

Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025

Reuters
·
Aug 01

Sihuan Pharmaceutical Sees Hy Revenue of RMB1,100 Mln, Net Profit Not Less Than RMB50 Mln

THOMSON REUTERS
·
Aug 01

Sihuan Pharmaceutical Announces Completion of First Patient Enrollment in Phase III Clinical Trial for Innovative Drug Anaprazole Sodium in Reflux Esophagitis

Reuters
·
Jul 30

Sihuan Pharmaceutical Files Next Day Disclosure to HKEX Announcing Repurchase of 20 Million Shares at HKD 1.08-1.1 Each

Reuters
·
Jun 17

Sihuan Pharmaceutical's Bireociclib Tablets' New Indication for HR+/HER2- Advanced Breast Cancer Accepted for Review by NMPA

Reuters
·
Jun 09

Sihuan Pharmaceutical Holdings Group Ltd. Conducted Annual General Meeting

Reuters
·
Jun 06